<!doctype html>
<html lang="en">
<head>
    <title>NAMetrics</title>
    <link rel="stylesheet" href="styles.css"> <!-- Optional for additional styling -->
</head>
<header>
 <img border="0" src="NAMetrics_Logo.png">
 <h1>A repository of open-source resources for evaluation and implementation of new approach methodologies in drug discovery and development</h2>
 </header>
<body>
<h2>What are NAMs?</h2>
<ul>
  <li><strong>New Approach Methodologies (NAMs)</strong> are modern, human-relevant, non-animal methods for preclinical drug development.</li>
  <li>Include a variety of tools such as:
    <ul>
      <li><strong>In vitro systems</strong>: organ-on-chip, 3D cell cultures, organoids.</li>
      <li><strong>In silico models</strong>: physiologically based pharmacokinetic (PBPK), quantitative systems pharmacology (QSP), digital twins.</li>
      <li><strong>Computational approaches</strong>: AI/ML, QSAR, mechanistic modeling.</li>
      <li><strong>Hybrid/combinatorial methods</strong>: Integration of in vitro and in silico for improved prediction.</li>
    </ul>
  </li>
</ul>

<h2>Why are NAMs Needed?</h2>
<ul>
  <li><strong>High clinical failure rates</strong>: Over 90% of drugs fail in clinical trials due to poor translation from animal data.</li>
  <li><strong>Scientific limitations</strong>: Animal models often lack disease relevance and human-specific biology.</li>
  <li><strong>Ethical concerns</strong>: Growing public and regulatory resistance to animal testing.</li>
  <li><strong>Financial impact</strong>: Failed translation drives up R&D costs (average ~$985 million per approved drug).</li>
  <li><strong>Regulatory support</strong>: Agencies like FDA, EMA, and ICH now endorse and encourage NAMs (e.g., FDA Modernization Act 3.0).</li>
</ul>
</body>
</html>
